0001005286-24-000020.txt : 20240216 0001005286-24-000020.hdr.sgml : 20240216 20240216161245 ACCESSION NUMBER: 0001005286-24-000020 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240213 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIFECORE BIOMEDICAL, INC. \DE\ CENTRAL INDEX KEY: 0001005286 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943025618 STATE OF INCORPORATION: DE FISCAL YEAR END: 0528 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27446 FILM NUMBER: 24648466 BUSINESS ADDRESS: STREET 1: 3515 LYMAN BOULEVARD CITY: CHASKA STATE: MN ZIP: 55318 BUSINESS PHONE: 9523684300 MAIL ADDRESS: STREET 1: 3515 LYMAN BOULEVARD CITY: CHASKA STATE: MN ZIP: 55318 FORMER COMPANY: FORMER CONFORMED NAME: LANDEC CORP \CA\ DATE OF NAME CHANGE: 19951222 8-K 1 lndc-20240213.htm 8-K lndc-20240213
FALSE000100528600010052862024-02-132024-02-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 13, 2024

LIFECORE BIOMEDICAL, INC.
(Exact name of registrant as specified in its charter)

 
Delaware
000-2744694-3025618
(State or other jurisdiction of incorporation)
(Commission file number)(IRS Employer Identification No.)
   3515 Lyman Boulevard
 Chaska,
Minnesota
55318
(Address of principal executive offices)(Zip Code)

(952) 368-4300
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common StockLFCRThe NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

1

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On February 13, 2024, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company’s securities.

The Staff Determination was issued because the Company has not filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023 (the “Form 10-K”) or its Quarterly Reports on Form 10-Q for the quarterly periods ended August 27, 2023 (the “First Quarter Form 10-Q”) and November 29, 2023 (the “Second Quarter Form 10-Q”) by the Extension Deadline (defined below).

The Company intends to appeal the Staff Determination before a Nasdaq Hearing Panel and seek a further stay of any suspension or delisting action pending the hearing process in accordance with the procedures set forth in the Staff Determination Letter. The Company is working diligently with its auditors to complete the previously disclosed restatement for the Company’s previously issued consolidated financial statements as of and for the fiscal years ended May 29, 2022 and May 30, 2021 included in the Company’s Annual Report on Form 10-K/A filed with the SEC, the Company’s unaudited consolidated financial statements as of and for the periods ending August 30, 2020, November 29, 2020, February 28, 2021, August 29, 2021, November 28, 2021, February 27, 2022, August 28, 2022, November 27, 2022 and February 26, 2023 included in the Company’s Quarterly Reports on Form 10-Q filed with the SEC, and to file the Form 10-K, First Quarter 10-Q and Second Quarter 10-Q.

As previously disclosed, Nasdaq had granted the Company a period of 180 calendar days from the prescribed due date of the Form 10-K, or until February 12, 2024 (the “Extension Deadline”), to file the Form 10-K, First Quarter Form 10-Q, and Second Quarter Form 10-Q to regain compliance with the Listing Rule. The Company previously disclosed the delay in and circumstances behind the late filing of each of the Form 10-K, the First Quarter Form 10-Q, and Second Quarter Form 10-Q in a Notification of Late Filing on Form 12b-25, filed with the SEC on August 14, 2023, October 10, 2023, and January 10, 2024, respectively.

The Company’s request for a hearing before the Nasdaq Hearing Panel to appeal the Staff Determination must be made no later than 4:00 p.m. Eastern Time on February 20, 2024. The hearing request will automatically stay the suspension of the Company’s securities for a period of 15 days from the date of the request. In connection with its request for a hearing, the Company also intends to request that the Staff Determination be further stayed pending the hearing process. According to the Staff Determination, hearings are typically scheduled to occur approximately 30-45 days after the date of a company’s hearing request. Following the hearing, the Hearings Panel will issue a decision, which the Company may further appeal to the Nasdaq Listing Council for review. The Company is working diligently to file the delinquent periodic reports as soon as possible to regain compliance with the Listing Rule. However, there can be no assurance that such periodic reports will be filed before any hearing occurs or that the Nasdaq Hearing Panel will grant the Company’s request for a stay pending the hearing process.

Item 7.01 Regulation FD Disclosure.

A press release, dated February 16, 2024, disclosing the Company’s receipt of the Staff Determination letter is attached hereto as Exhibit 99.1.

The information furnished in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished as part of this report:

Exhibit No.Description
104
Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document.




2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 16, 2024
LIFECORE BIOMEDICAL, INC.
By:
/s/ John D. Morberg
John D. Morberg
Chief Financial Officer
3
 EX-99.1 2 lifecore-pressrelease.htm EX-99.1 Document

Exhibit 99.1

Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities

CHASKA, Minn., February 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that on February 13, 2024 it received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated which could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company’s securities.

The Staff Determination was issued because the Company has not filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023 (the “Form 10-K”) or its Quarterly Reports on Form 10-Q for the quarterly periods ended August 27, 2023 (the “First Quarter Form 10-Q”) and November 29, 2023 (the “Second Quarter Form 10-Q”) by the Extension Deadline (defined below).

The Company intends to appeal the Staff Determination before a Nasdaq Hearing Panel and seek a further stay of any suspension or delisting action pending the hearing process in accordance with the procedures set forth in the Staff Determination Letter. The Company is working diligently with its auditors to complete the previously disclosed restatement for the Company’s previously issued consolidated financial statements as of and for the fiscal years ended May 29, 2022 and May 30, 2021 included in the Company’s Annual Report on Form 10-K/A filed with the SEC, the Company’s unaudited consolidated financial statements as of and for the periods ending August 30, 2020, November 29, 2020, February 28, 2021, August 29, 2021, November 28, 2021, February 27, 2022, August 28, 2022, November 27, 2022 and February 26, 2023 included in the Company’s Quarterly Reports on Form 10-Q filed with the SEC, and to file the Form 10-K, First Quarter 10-Q and Second Quarter 10-Q.

As previously disclosed, Nasdaq had granted the Company a period of 180 calendar days from the prescribed due date of the Form 10-K, or until February 12, 2024 (the “Extension Deadline”), to file the Form 10-K, First Quarter Form 10-Q, and Second Quarter Form 10-Q to regain compliance with the Listing Rule. The Company previously disclosed the delay in and circumstances behind the late filing of each of the Form 10-K, the First Quarter Form 10-Q, and Second Quarter Form 10-Q in a Notification of Late Filing on Form 12b-25, filed with the SEC on August 14, 2023, October 10, 2023, and January 10, 2024, respectively.

The Company’s request for a hearing before the Nasdaq Hearing Panel to appeal the Staff Determination must be made no later than 4:00 p.m. Eastern Time on February 20, 2024. The hearing request will automatically stay the suspension of the Company’s securities for a period of 15 days from the date of the request. In connection with its request for a hearing, the Company also intends to request that the Staff Determination be further stayed pending the hearing process. According to the Staff Determination, hearings are typically scheduled to occur approximately 30-45 days after the date of a company’s hearing request. Following the hearing, the Hearings Panel will issue a decision, which the Company may further appeal to the Nasdaq Listing Council for review. The Company is working diligently to file the delinquent periodic reports as soon as possible to regain compliance with the Listing Rule. However, there can be no assurance that such periodic reports will be filed before any hearing occurs or that the Nasdaq Hearing Panel will grant the Company’s request for a stay pending the hearing process.

About Lifecore Biomedical
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore Biomedical, Inc. brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit the Company’s website at www.lifecore.com.

Forward-Looking Statements
This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company’s appeal to the Nasdaq Hearings Panel and request for a stay of the



Nasdaq delisting process and the timing of the filing of the Company’s delinquent periodic reports, which reflect the Company’s expectations based upon currently available information and data.

Because such statements are based on the Company’s current expectations and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with Listing Rule, the Company’s ability to become current with its reports with the SEC, the risk that the completion and filing of the delinquent periodic reports will take longer than expected, and the risk that Nasdaq does not grant the Company’s request for a stay pending the hearing process or does not grant the Company’s request for continued listing. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K/A. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Lifecore Biomedical, Inc. Contact Information:
Jeff Sonnek
(646) 277-1263
jeff.sonnek@icrinc.com


 EX-101.SCH 3 lndc-20240213.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lndc-20240213_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 lndc-20240213_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information Document
Feb. 13, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 13, 2024
Entity Registrant Name LIFECORE BIOMEDICAL, INC.
Entity Central Index Key 0001005286
Entity Incorporation, State or Country Code DE
Entity File Number 000-27446
Entity Tax Identification Number 94-3025618
Entity Address, Address Line One 3515 Lyman Boulevard
Entity Address, City or Town Chaska,
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55318
City Area Code 952
Local Phone Number 368-4300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol LFCR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://landec.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports lndc-20240213.htm lndc-20240213.xsd lndc-20240213_lab.xml lndc-20240213_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lndc-20240213.htm": { "nsprefix": "lndc", "nsuri": "http://landec.com/20240213", "dts": { "inline": { "local": [ "lndc-20240213.htm" ] }, "schema": { "local": [ "lndc-20240213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lndc-20240213_lab.xml" ] }, "presentationLink": { "local": [ "lndc-20240213_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://landec.com/role/DocumentandEntityInformationDocument", "longName": "0000001 - Document - Document and Entity Information Document", "shortName": "Document and Entity Information Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lndc-20240213.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lndc-20240213.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001005286-24-000020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001005286-24-000020-xbrl.zip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end XML 16 lndc-20240213_htm.xml IDEA: XBRL DOCUMENT 0001005286 2024-02-13 2024-02-13 false 0001005286 8-K 2024-02-13 LIFECORE BIOMEDICAL, INC. DE 000-27446 94-3025618 3515 Lyman Boulevard Chaska, MN 55318 952 368-4300 false false false false Common Stock LFCR NASDAQ false